Zurich Cantonal Bank
NRIX icon

Zurich Cantonal Bank’s Nurix Therapeutics NRIX Stock Holding History

Zurich Cantonal Bank’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$634K Buy
40,928
+9,737
+31% +$161K ﹤0.01% 1708
2025
Q4 		$592K Buy
31,191
+12,362
+66% +$178K ﹤0.01% 1687
2025
Q3 		$174K Hold
18,829
– – ﹤0.01% 2251
2025
Q2 		$214K Hold
18,829
– – ﹤0.01% 2102
2025
Q1 		$224K Buy
18,829
+2,260
+14% +$37.8K ﹤0.01% 2042
2024
Q4 		$312K Buy
16,569
+1,401
+9% +$32.1K ﹤0.01% 1922
2024
Q3 		$341K Sell
15,168
-39
-0.3% -$883 ﹤0.01% 1801
2024
Q2 		$317K Buy
15,207
+13,444
+763% +$209K ﹤0.01% 1793
2024
Q1 		$25.9K Buy
+1,763
New +$19K ﹤0.01% 2614
2023
Q4 		– Sell
-5,482
Closed -$43.1K – 2769
2023
Q3 		$43.1K Sell
5,482
-1
-0% -$9 ﹤0.01% 2626
2023
Q2 		$54.8K Hold
5,483
– – ﹤0.01% 2593
2023
Q1 		$48.7K Sell
5,483
-829
-13% -$8.64K ﹤0.01% 2601
2022
Q4 		$69.3K Buy
6,312
+1,194
+23% +$14.4K ﹤0.01% 2486
2022
Q3 		$67K Hold
5,118
– – ﹤0.01% 2474
2022
Q2 		$65K Hold
5,118
– – ﹤0.01% 2480
2022
Q1 		$72K Buy
5,118
+1,071
+26% +$19K ﹤0.01% 2418
2021
Q4 		$117K Buy
+4,047
New +$123K ﹤0.01% 2423

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Zurich Cantonal Bank's NRIX Position: Q1 2026 in Review

Zurich Cantonal Bank increased its Nurix Therapeutics (NRIX) stake by 31% in Q1 2026, buying an estimated $161K and bringing the position to 40,928 shares worth $634K. The position accounts for ﹤0.01% of the portfolio, ranked #1708.

Zurich Cantonal Bank first reported a position in NRIX in Q4 2021 and has held it in 17 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Zurich Cantonal Bank held 40,928 shares of Nurix Therapeutics worth $634K as of Q1 2026.
  • Zurich Cantonal Bank bought 9,737 Nurix Therapeutics shares in Q1 2026, an estimated $161K.
  • Nurix Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1708 holding.
  • Zurich Cantonal Bank first reported a position in Nurix Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.